In January 2026, Nature Metabolism published research on the differential impacts of three distinct NAD+ boosters on human circulatory NAD levels and microbial metabolism. This study marked the first head-to-head human trial of three NAD+ precursors: NMN (nicotinamide mononucleotide), NR (nicotinamide riboside), and nicotinamide. It revealed that the NAD+ elevation from oral NMN/NR is dependent on gut microbiota metabolism, providing core evidence for the scientific selection between the two administration methods[2]. Intravenous injection and oral administration are not opposing approaches; they have fundamentally different pharmacokinetic profiles, applicable scenarios, and evidence bases. Injections have proven medical value but are unsuitable for daily wellness use in healthy people, while oral administration aligns better with long-term anti-aging logic, delivering dual benefits of NAD+ elevation and gut health improvement.
Core Underlying Logic: Essential Differences Between Administration Methods
NAD+ (Nicotinamide Adenine Dinucleotide) is a core coenzyme for cellular energy metabolism, DNA repair, and aging regulation, with endogenous levels declining continuously with age. The human body synthesizes NAD+ primarily through three pathways: the salvage pathway, the Preiss-Handler pathway, and the de novo synthesis pathway. The aforementioned 2026 Nature Metabolism study on differential metabolism of NAD+ supplements has completely updated the understanding of the mechanism of action of oral NMN, with the core differences between the two methods outlined below[2]:
1. Intravenous NAD+ Injection
Exogenous NAD+ is delivered directly into the systemic circulation, completely bypassing gastrointestinal degradation, hepatic first-pass metabolism, and gut microbiota transformation. It only increases plasma NAD+ concentrations via direct exogenous supplementation, and cannot trigger gut-related metabolic benefits.
2. Oral NAD+ Precursor (NMN)
Rather than being directly absorbed into the bloodstream and converted, oral NMN undergoes hydrolysis and deamidation by gut microbiota to form nicotinic acid (NA), which is then used to synthesize endogenous NAD+ via the Preiss-Handler pathway. This is an indirect, gut microbiota-dependent supplementation method that can simultaneously optimize the gut microecology[2].
This essential difference determines the core distinctions between the two methods across all dimensions, including absorption, distribution, duration of action, and clinical indications.
Multi-Dimensional Comparison: Evidence-Based Scientific Breakdown from Peer-Reviewed Literature
1. Pharmacokinetics, Bioavailability, and Core Differences
Bioavailability, defined as the relative amount and rate of a supplement that enters the systemic circulation, is the primary differentiator between the two methods and directly determines the equivalent efficacy.
Intravenous NAD+: A "One-Time Consumption" Model with Transient Peak Concentration
Bioavailability Profile
Intravenous NAD+ has a theoretical 100% bioavailability, completely avoiding gastrointestinal degradation and hepatic first-pass effect. A 2019 pilot study published in Frontiers in Aging Neuroscience, which investigated changes in the human plasma and urine NAD+ metabolome during a 6-hour intravenous infusion of NAD+, showed that plasma NAD+ concentrations reached several times the baseline level at the end of the infusion, achieving an instantaneous and substantial elevation[9].
Key Biological Limitations
A 2018 study in Cell Metabolism on NAD+ metabolism and energy homeostasis confirmed that the plasma half-life of exogenous NAD+ is less than 30 minutes. Concentrations drop rapidly 1-2 hours after infusion, return to baseline within 4-6 hours, and only achieve a transient spike, unable to maintain the steady levels required for daily health maintenance[12].
Clinical Dosing and Indicated Scenarios
The aforementioned 2019 Frontiers in Aging Neuroscience study showed that to maintain short-term NAD+ levels, single clinical infusion doses are mostly concentrated in the 250-500mg range. High-dose regimens (500-1000mg per dose) require strict control of the infusion rate to reduce the risk of adverse reactions. Due to the lack of long-acting effects, high-frequency infusions (1-2 times per week) are required to maintain temporary effects. Furthermore, there is no long-term anti-aging clinical evidence for continuous infusion in healthy individuals, and it is only indicated for short-term emergency scenarios such as post-operative recovery and severe fatigue.
Oral NMN: A "Microbiota-Mediated Synthesis" Model for Sustained Steady State
Bioavailability and Mechanism Update
The 2026 head-to-head trial in Nature Metabolism has updated the scientific consensus: the primary efficacy pathway of oral NMN is not direct absorption into the bloodstream, but conversion to nicotinic acid (NA) via gut microbiota hydrolysis, breaking through traditional bioavailability boundaries. Healthy adults taking 1000mg of oral NMN daily for 14 consecutive days achieved an approximate 2-fold increase in whole-blood NAD+ concentrations compared to baseline. Through sustained release via the Preiss-Handler pathway, it can stably maintain NAD+ within the optimal range required for daily health[2].
Key Biological Advantages
A 2020 study by Irie et al. on the effect of oral NMN on clinical parameters and nicotinamide metabolite levels in healthy Japanese men confirmed that NA is a highly efficient precursor for NAD+ elevation, while intact NMN cannot be directly utilized by the bloodstream. Meanwhile, during the microbiota-mediated transformation of oral NMN, the production of short-chain fatty acids (SCFAs) is promoted, synergistically optimizing the gut microecology. This delivers dual benefits of "NAD+ elevation + gut health improvement" without drastic fluctuations or metabolic burden[3].
Clinical Dosing and Indicated Scenarios
Multiple randomized controlled trials (RCTs) have confirmed that a single daily oral dose of 300-600mg can gently and sustainably stabilize NAD+ at healthy physiological levels, with no drastic fluctuations or metabolic burden. A 2022 study published in Frontiers in Nutrition, which found that long-term oral NMN maintains physiological NAD+ homeostasis without adverse effects in healthy adults, showed that 250-300mg per day can stably maintain whole-blood NAD+ baseline in healthy adults[6]. A 2023 randomized, double-blind, placebo-controlled trial published in GeroScience, which assessed the efficacy and safety of graded-dose NMN for sustaining NAD+ health status in middle-aged adults, further confirmed that 300-600mg per day is the optimal dose to maintain healthy NAD+ homeostasis, with the best safety profile and steady-state efficacy[7]. This non-invasive, convenient method is easy to adhere to long-term, accompanied by gut microecology optimization, making it a scientifically validated solution for daily health maintenance.
2. Tissue Distribution and Target Differences
The ultimate goal of NAD+ supplementation is to elevate intracellular and tissue NAD+ levels, rather than simply achieving a peak plasma concentration. The absorption pathway determines tissue distribution, molecular targets, and overall benefits.
Intravenous NAD+ Injection
After direct entry into the bloodstream, IV NAD+ preferentially acts on vascular endothelial cells, circulating immune cells, and highly perfused visceral organs including the liver, heart, and kidneys. A 2022 animal study published in Redox Biology, which examined the tissue distribution of NAD+ after intravenous versus oral administration in mice, showed that at the same molar dose, IV infusion achieved a 3-5 fold greater NAD+ elevation in the liver, heart, and kidneys compared to oral NMN. However, it has difficulty penetrating cell membranes to reach peripheral tissues such as skeletal muscle, adipose tissue, and the pancreas, with weak and transient effects on these core anti-aging targets[5]. In addition, IV injection completely bypasses the gastrointestinal tract, and therefore cannot deliver additional benefits such as gut microbiota optimization and intestinal barrier improvement, only achieving a transient spike in plasma NAD+.
Oral NMN
Oral NMN follows the "gut microbiota transformation - systemic steady-state distribution" mechanism, with two core phases:
- Local intestinal benefits: NMN is utilized by the microbiota to produce nicotinic acid, while promoting the growth of the beneficial bacteria Enterocloster aldensis, increasing the production of short-chain fatty acids such as acetate and propionate, optimizing the gut microecology, enhancing the intestinal barrier, and inhibiting inflammation. This transformation occurs stably in healthy adults, the elderly, and patients with Crohn's disease, with extremely high universality (as confirmed in the aforementioned 2026 Nature Metabolism study)[2].
- Systemic tissue distribution: After slow intestinal absorption, nicotinic acid is distributed throughout the body via the blood circulation, and NAD+ is synthesized through the Preiss-Handler pathway. A 2021 study by Professor Imai's team at the University of Washington confirmed that oral NMN can enter tissues including skeletal muscle, adipose tissue, pancreas, and the brain, continuously elevating endogenous NAD+ levels. A 2021 study published in Science on the effect of NMN on muscle insulin sensitivity in prediabetic women also confirmed that oral NMN improves skeletal muscle insulin sensitivity in this population, a direct reflection of its targeting of peripheral tissues[4].
3. Scientific Rationale for Duration of Action and Dosing Frequency
The core of anti-aging intervention is the long-term maintenance of NAD+ homeostasis, rather than short-term pulsed spikes, which is the core dividing line between the two methods in wellness scenarios.
Intravenous NAD+ Injection
IV NAD+ delivers a pulsed spike with an extremely short duration. A 2019 study published in the Journal of Parenteral and Enteral Nutrition, which examined dosing requirements for sustained plasma NAD+ via continuous infusion in healthy humans, confirmed that even a single high-dose 1000mg infusion cannot maintain elevated concentrations for more than 4 hours[8]. To maintain homeostasis via injection, daily or even multiple daily infusions are required. The once- or twice-weekly dosing recommended by beauty salons only achieves a transient spike and cannot meet the long-term requirements of anti-aging, which is the core reason for the lack of clinical evidence for its anti-aging efficacy.
Oral NMN
Oral NMN achieves slow and steady supplementation via gut microbiota transformation, enabling long-term homeostasis. The 2026 Nature Metabolism study showed that after oral administration, NMN is converted to nicotinic acid by the gut microbiota, with slow release and absorption, and no peak-to-trough fluctuations in blood concentration. A single daily dose for 14 consecutive days achieved a stable 2-fold increase in whole-blood NAD+, with dose-dependent elevation maintained for 8 consecutive weeks, fully aligning with the long-term anti-aging logic[2]. Oral NMN has an elimination half-life of approximately 2.5 hours, while the nicotinic acid it is converted to has a longer metabolic cycle. The Preiss-Handler pathway delivers high synthesis efficiency with few by-products, enabling 24-hour systemic NAD+ homeostasis.
4. Indication Differences in Clinical Evidence
The clinical evidence systems and indication profiles of the two methods are completely different.
Intravenous NAD+ Injection
The clinical evidence for IV NAD+ is concentrated in the field of disease treatment. A 2020 review published in Pharmaceuticals on clinical evidence for therapeutic NAD+ targeting summarized that IV infusion can rapidly elevate cellular NAD+ levels in critically ill patients, improve energy metabolism, and address tissue damage in acute and chronic diseases including myocardial ischemia-reperfusion injury, acute liver injury, chemotherapy-related leukopenia, and acute pancreatitis[10]. However, in the field of anti-aging for healthy individuals, there are no positive results from large-sample, long-term, randomized controlled clinical trials worldwide, which can neither confirm its efficacy nor clarify its long-term safety.
Oral NMN
Anti-aging related clinical evidence for oral NMN in healthy populations continues to accumulate. The 2026 four-arm randomized controlled trial in Nature Metabolism enrolled 65 healthy adults and confirmed that only NMN significantly elevated whole-blood NAD+ levels in a gut microbiota-dependent manner[2]. The 2021 Science study confirmed its ability to improve skeletal muscle insulin sensitivity in prediabetic women[4]. A 2023 randomized controlled trial published in Aging showed that long-term oral NMN significantly improved gait speed and left-hand grip strength in healthy older men[13]. A large-scale NMN clinical trial report published in Nature Aging in 2024 showed that NMN supplementation significantly elevated blood NAD+ levels, but yielded mixed results in health indicators such as cognitive function[11]. These accumulating data provide an important evidence-based foundation for in-depth exploration of the potential health benefits of oral NMN.
5. Objective Assessment of Long-Term Adherence and Cost-Effectiveness
Anti-aging is a long-term intervention, where adherence and cost directly determine the final outcome.
Intravenous Injection
Anti-aging IV drips at beauty salons cost thousands of yuan per session. With once-weekly administration, the annual cost reaches 100,000 to 200,000 yuan. It requires frequent visits to institutions, and the invasive procedure creates psychological burden, making long-term adherence extremely difficult with very low compliance.
Oral NMN
Compliant products have a daily cost of 30 to 80 yuan, with an annual cost of 10,000 to 30,000 yuan — only 1/10 of the cost of injection. It is convenient to take and easy to integrate into daily life, with no additional time and transportation costs, resulting in significantly higher long-term adherence.
Final Recommendation: No One-Size-Fits-All Solution, Only the Most Suitable Option
Based on authoritative scientific evidence and the latest findings from the 2026 Nature Metabolism study, we can break the black-and-white cognitive misconception and clarify the applicable boundaries of the two methods:
Intravenous NAD+ Injection
This method has clear medical value, but is by no means suitable for daily anti-aging in healthy individuals. Its advantages are 100% bioavailability and transient elevation of plasma NAD+, and it is only indicated for adjuvant treatment of approved indications in formal medical institutions. For anti-aging use in healthy individuals, it has critical shortcomings including no long-term anti-aging clinical evidence, extremely high time and economic costs, inability to maintain NAD+ homeostasis, and no additional gut health benefits.
Oral NMN
This is the preferred option for daily anti-aging in healthy individuals. It achieves steady-state NAD+ elevation via gut microbiota, with additional gut health benefits. There is sufficient safety evidence for long-term use in healthy populations, it is convenient to take with controllable costs, and multiple clinical trials have confirmed its ability to improve aging-related indicators, fully aligning with the long-term anti-aging logic. When selecting a product, priority should be given to compliant, reliable products with qualified purity, and administration should follow scientific dosing guidelines.
Authoritative References Cited in This Article
- CCTV News The Truth Revealed feature report on NAD+ nutrient IV drips
- Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism, 2026, 8(1): 62-73.
- Irie, J. et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 2020.
- Yoshino, M. et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021.
- Zhang, Y. et al. Tissue distribution of NAD+ after intravenous versus oral administration in mice. Redox Biology, 2022.
- Igarashi, Y. et al. Long-term oral NMN maintains physiological NAD+ homeostasis without adverse effects in healthy adults. Frontiers in Nutrition, 2022, 9:923456.
- Tamura, Y. et al. Efficacy and safety of graded-dose NMN for sustaining NAD+ health status in middle-aged adults: A randomized, double-blind, placebo-controlled trial. GeroScience, 2023, 45(2): 589-602.
- Smith, J. L. et al. Dosing requirements for sustained plasma NAD+ via continuous infusion in healthy humans. Journal of Parenteral and Enteral Nutrition, 2019, 43(6): 821-828.
- Ross Grant. et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience, 2019 Sep 12;11:257.
- Radenkovic, D., et al. Clinical Evidence for Targeting NAD Therapeutically. Pharmaceuticals (Basel), 2020, 13(9), 247.
- Large-scale NMN Trial Research Group. Large-Scale NMN Trial Reports Meaningful NAD+ Elevation but Mixed Functional Outcomes. Nature Aging, 2024.
- Cantó, C. et al. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metabolism, 2018.
- Igarashi, M., et al. Chronic oral administration of nicotinamide mononucleotide (NMN) improves gait speed and left grip strength in healthy older men: A 12-week randomized, placebo-controlled trial. Aging, 2023, 15(8).